Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07388628

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

The objectives of this registry study are to:

1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3. Identify potential sub-groups, assess their risk-benefit- and safety profile. 4. Changes in SOFA score D0 to SOFA Score D7.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin, Magdeburg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. Change in SOFA score D0 to SOFA Score D7 (or after last ARTICE® treatment, if later as D7).

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)

  2. Changes in general SOFA score and SOFA sub scores.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)

  3. Changes in standard lab and inflammatory biomarkers.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    standard lab and inflammatory biomarkers for exampample are: ferritine, total bilirubin, kreatinine, CRP, lactate, gammaglobuline, amount of the different blodd cell types, like neutrophils, lymphocytes

  4. Hospital survival rates.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  5. Apache II Score.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    APACHE II is a clinical rating system for evaluating the severity of an illness and the risk of death in intensive care medicine; score includes information on the patient's current condition, age and concomitant diseases, values are collected over 24 hours, highest value is included in calcutaion; the score can be at minimum 0 points (lightly risk of death) and at maximum 71 (very high risk of death)

  6. Length of ICU stay (days).

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  7. Mechanical ventilation days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  8. Renal replacement therapy days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  9. Vasopressor therapy days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  10. Frequency of secondary infections.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  11. Type of secondary infections: it will be divided into viral, bacterial or fungi infection.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    It is recorded whether the infection is viral, bacterial, or caused by fungi. And in case of bacterial infection it will be recorded weather, it is gram-positive or gram-negative bacterial infection.

  12. Changes in the physiological parameter heartrate.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    as physiological parameter will be measured heartrate in bpm

  13. Changes in physiological parameter blood pressure.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    as physiological parameter will be measured systolic and diastolic blood pressure in mmHg.

  14. Changes in physiological parameter body temperature.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    as physiological parameter will be measured body temperature in °C

  15. Changes in physiological parameter mean arterial pressure.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

    as physiological parameter will be measured mean arterial pressure in mmHG

  16. Complications related to the ARTICE® therapy application.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Jens Altrichter, Dr. med.

CONTACT

[email protected]

+49 381 440 703 0

Judith Hey, M. Sc.

CONTACT

[email protected]

+49 1772216033

Sponsors and collaborators

Lead sponsor

Artcline GmbH

Industry

Registry information

Official study title

ARTISTRY - ARTICE® Therapy Registry Study

Acronym: ARTistry

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Feb 5, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.